Eliquis Market Size and Share: 2025 Analysis of Rising Business Opportunities with Prominent Investment, Forecast to 2032 by Pfizer Inc. and Bristol-Myers Squibb Company

The Eliquis market is witnessing significant industry momentum driven by increasing prevalence of cardiovascular disorders and a growing emphasis on anticoagulant therapies worldwide. Innovations in drug delivery and expanded clinical indications have further amplified the market scope, positioning Eliquis as a pivotal player in managing thromboembolic events. The Global Eliquis Market size is estimated to be valued at USD 7.2 billion in 2025 and is expected to reach USD 10.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032. This robust market forecast underscores the rising demand supported by favorable reimbursement policies and enhanced physician awareness, collectively driving sustained market revenue and industry share growth.

➔ Request a sample Report Now to explore the full potential: https://www.coherentmarketinsights.com/insight/request-sample/8193

➤Analyst Opinion

● The growing market share of Eliquis is closely linked to its expanding production capacity and strategic supply chain enhancements. In 2024, Pfizer Inc. and Bristol-Myers Squibb Company reported a 12% increase in manufacturing output, ensuring steady supply amid rising global demand. This supply-side indicator confirms the market's ability to meet the escalating consumption rates which directly impact market size and revenue.
● Demand-side dynamics reveal a consistent rise in prescriptions across cardiology and orthopedics, with Eliquis adoption increasing by 15% in 2025 compared to the previous year. Market analysis shows that broader use cases, including stroke prevention in non-valvular atrial fibrillation, have significantly contributed to this growth, reinforcing market growth strategies focused on diversified clinical applications.
● Micro-indicators such as pricing trends demonstrate Eliquis's competitive positioning. Despite price fluctuations in 2024, the drug maintained a premium pricing model supported by superior clinical outcomes, enabling it to capture a larger segment of the oral anticoagulant market. Data from healthcare providers indicate a 7% year-over-year increase in average treatment duration, further bolstering market revenue.
● Nano-size indicators highlight regional import-export patterns, where North America and Europe led Eliquis imports, accounting for 65% of the total market revenue in 2025. This reflects the uneven market penetration and underscores the potential for growth in emerging markets, shaping future market forecast models and industry trends.

➤Market Taxonomy and Regional coverage of Report

● Comprehensive Taxonomy of the Report:
» By Dosage Form: Tablet, Injectable, Others
» By Application: Stroke Prevention, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Others
» By End Use: Hospitals, Clinics, Ambulatory Surgical Centers, Others

● Regional and Country Analysis:
» North America: U.S. and Canada
» Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
» Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
» Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
» Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA

➔ Elevate your business strategy with comprehensive market data. Request a sample report now: https://www.coherentmarketinsights.com/insight/request-sample/8193

➤Leading Companies of the Market

● Pfizer Inc.
● Bristol-Myers Squibb Company
● Teva Pharmaceutical Industries Ltd.
● Mylan N.V.
● Sandoz International GmbH
● Bayer AG
● Johnson & Johnson Services, Inc.
● Daiichi Sankyo Company, Limited
● Novartis AG
● Sanofi S.A.
● Aurobindo Pharma Limited
● Lupin Limited
● Sun Pharmaceutical Industries Ltd.
● Cipla Limited
● Dr. Reddy's Laboratories Ltd.
● Strategic alliances such as the collaboration between Pfizer Inc. and Bristol-Myers Squibb have led to enhanced R&D capabilities, resulting in expanded indications for Eliquis and a reported 18% boost in global sales in 2024. Additionally, market players have adopted aggressive marketing and patient awareness programs, increasing Eliquis prescriptions by 14% across North America. Some companies have also pursued pipeline expansion through biosimilar developments, which is anticipated to impact Eliquis's competitive landscape in coming years.

➤Key Growth Drivers Fueling Market Expansion

The Eliquis market growth is primarily fueled by the increasing prevalence of atrial fibrillation and venous thromboembolism worldwide, where the patient pool is projected to rise by over 20% by 2030 according to the American Heart Association. Furthermore, enhanced clinical trial outcomes demonstrating Eliquis's efficacy and safety profile have substantially elevated its adoption over alternative anticoagulants, leading to a 10% increase in market revenue in 2024. Regulatory approvals for extended indications and favorable reimbursement policies in developed economies have further broadened Eliquis's market scope. Lastly, the rising trend of outpatient care and ambulatory surgical procedures has escalated demand for oral anticoagulants, significantly impacting industry size and business growth trajectories.

➔ Get Instant Access! Purchase Research Report and receive a 25% Discount: https://www.coherentmarketinsights.com/insight/buy-now/8193

➤Key Reasons for Buying the Eliquis Report

✦ Comprehensive analysis of the changing competitive landscape
✦ Assists in decision-making processes for the businesses along with detailed strategic planning methodologies
✦ The report offers forecast data and an assessment of the Eliquis
✦ Helps in understanding the key product segments and their estimated growth rate
✦ In-depth analysis of market drivers, restraints, trends, and opportunities
✦ Comprehensive regional analysis of the Eliquis
✦ Extensive profiling of the key stakeholders of the business sphere
✦ Detailed analysis of the factors influencing the growth of the Eliquis

➤ Emerging Trends and Market Shift

Recent industry trends highlight a paradigm shift towards personalized medicine, with Eliquis's dosing regimens increasingly tailored based on patient-specific risk factors, enhancing therapeutic outcomes. Data from 2025 clinical settings reveal a 9% reduction in adverse events due to this approach. Additionally, digital health integration, including apps for medication adherence, is gaining traction, improving Eliquis's market dynamics by reducing treatment discontinuation rates. Another critical trend is the rising acceptance of Eliquis in emerging economies, driven by improved healthcare infrastructure and expanding insurance coverage, which collectively influence the market forecast and revenue streams.

➤High-Impact Market Opportunities by Segment and Region

The tablet dosage form segment presents a high-impact opportunity with growing preference due to ease of administration and patient compliance, projected to account for 70% of Eliquis market revenue by 2030. In terms of application, stroke prevention remains the most lucrative segment, driven by increasing atrial fibrillation diagnoses and corresponding treatment protocols, which expanded by 12% in 2024 alone. The hospital end-use segment is poised for notable growth owing to rising inpatient procedures requiring anticoagulant therapies, influencing overall market share positively. Regionally, North America offers the most significant opportunity due to advanced healthcare systems, high patient awareness, and reimbursement policies, which collectively contribute to over 40% of the Eliquis market size in 2025 and are expected to increase steadily.

❓ Frequently Asked Questions

1. Who are the dominant players in the Eliquis market?
Pfizer Inc. and Bristol-Myers Squibb Company lead the Eliquis market, leveraging strong R&D and strategic partnerships to maintain significant market share.

2. What will be the size of the Eliquis market in the coming years?
The Eliquis market size is projected to grow from USD 7.2 billion in 2025 to approximately USD 10.3 billion by 2032, with a CAGR of 5.2%.

3. Which end users industry has the largest growth opportunity?
Hospitals represent the largest growth opportunity, driven by increasing inpatient anticoagulant therapy requirements and procedural volumes.

4. How will market development trends evolve over the next five years?
The market will see a shift towards personalized dosing and digital adherence tools, along with expanded usage in emerging economies, influencing overall growth.

5. What is the nature of the competitive landscape and challenges in the Eliquis market?
The competitive landscape is characterized by strategic collaborations and biosimilar developments, with challenges including pricing pressures and regulatory hurdles.

6. What go-to-market strategies are commonly adopted in the Eliquis market?
Companies focus on strategic partnerships, clinical trial expansions, patient awareness campaigns, and pricing optimization to enhance market penetration and revenue growth.

Author of this marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from Openpr her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Contact Us:

Mr. Shah
Coherent Market Insights
533 Airport Boulevard,
Suite 400, Burlingame,
CA 94010, United States
US: + 12524771362
UK: +442039578553
AUS: +61-8-7924-7805
India: +91-848-285-0837

This release was published on openPR.